Premium
Icariin and its phosphorylated derivatives alleviate intestinal epithelial barrier disruption caused by enterotoxigenic Escherichia coli through modulate p38 MAPK in vivo and in vitro
Author(s) -
Xiong Wen,
Huang Jing,
Li Xueying,
Zhang Zhu,
Jin Meilan,
Wang Jian,
Xu Yuwei,
Wang Zili
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.201902265r
Subject(s) - barrier function , p38 mitogen activated protein kinases , enterotoxigenic escherichia coli , mapk/erk pathway , in vivo , intestinal epithelium , oxidative stress , pharmacology , chemistry , microbiology and biotechnology , biology , phosphorylation , epithelium , biochemistry , escherichia coli , genetics , enterotoxin , gene
Abstract The natural product icariin (ICA) and its phosphorylated derivatives (pICA) have been shown to have outstanding anti‐inflammatory and antioxidant properties. This study was to explore the protective effects of ICA and pICA on the intestinal epithelium of enterotoxigenic Escherichia coli (ETEC)‐induced piglet diarrhea and its underlying mechanisms in vivo and in vitro. ETEC K88 increased pro‐inflammatory cytokine expression, activated oxidative stress and inhibited antioxidant enzyme activity, induced phosphorylated p38 MAPK gene and protein expression, disrupted intestinal barrier function, and led to diarrhea in piglets. Pretreatment with ICA and pICA effectively alleviated ETEC‐induced intestinal barrier dysfunction in vivo and in vitro. Pretreatment with p38 MAPK inhibitor (SB203580) significantly rescued the IPEC‐J2 cells barrier function damaged by ETEC challenge. However, pretreatment with p38 MAPK activator (anisomycin) did not alleviated the IPEC‐J2 cells barrier function damaged by ETEC challenge. Our data demonstrated that ICA and pICA regulate the inflammatory response and oxidative stress of intestinal epithelial cells by inhibiting the expression of p38 MAPK, thereby alleviating ETEC K88‐induced disruption of intestinal barrier function and intestinal permeability. These findings provide new insights into the prevention and treatment of intestinal barrier dysfunction induced by ETEC K88.